Iveda Solutions, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Iveda Solutions, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $4.47M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.92M | Mar 31, 2023 |
| FY2015 | Dec 31, 2015 | $3.07M | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | $2.19M | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $3.35M | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $3.61M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $2.82M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $940.0K | May 11, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.28M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.50M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $4.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.92M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.48M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.27M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.30M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.07M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $963.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $832.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $492.7K | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | $681.6K | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | $573.5K | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $615.9K | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $378.5K | Mar 31, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.98M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.14M) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | ($3.35M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.00M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.60M) | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | ($3.79M) | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | ($5.66M) | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | ($6.80M) | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | ($3.84M) | Mar 31, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.07M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.04M) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | ($3.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.73M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.23M) | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | ($3.34M) | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | ($4.96M) | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | ($6.80M) | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | ($3.84M) | Mar 31, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.8K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $363.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $797.1K | Jun 16, 2025 |
| FY2015 | Dec 31, 2015 | $264.8K | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | $304.1K | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $285.8K | Mar 16, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.33M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.31M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $4.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.56M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.72M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.03M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.33M) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | ($5.41M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($145.6K) | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | ($2.66M) | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | ($5.03M) | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | ($3.61M) | Mar 16, 2015 |
| FY2012 | Dec 31, 2012 | ($3.33M) | Apr 1, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.6K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $85.6K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $14.2K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $24.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $21.9K | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | $27.4K | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | $268.7K | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $157.2K | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $338.8K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $153.6K | Apr 1, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.43M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.31M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $9.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | $2.45M | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | $3.48M | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $3.68M | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $4.92M | Mar 31, 2014 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $1.44M | May 11, 2012 |
| FY2011 | Dec 31, 2010 | $528.6K | May 11, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.51M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $4.65M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $7.57M | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | ($777.3K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($3.71M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($2.64M) | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | ($1.63M) | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | ($756.4K) | Jun 10, 2016 |
| FY2015 | Dec 31, 2013 | $521.8K | Jun 10, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2012 | $841.0K | Apr 1, 2013 |
| FY2011 | Dec 31, 2011 | $841.0K | Mar 30, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.37M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($53.18M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($49.20M) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | ($44.71M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($41.36M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($38.32M) | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | ($31.91M) | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | ($27.49M) | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | ($21.80M) | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | ($15.00M) | Mar 31, 2014 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2025 | $5.16M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 1.03M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.63M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 1.96M | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | $4.74M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $7.31M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $249.5K | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | $206.9K | Jun 10, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $393.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $376.2K | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | $190.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $338.8K | Mar 31, 2023 |
| FY2015 | Dec 31, 2014 | $34.6K | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | $550.8K | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $143.4K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $10.5K | Apr 1, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | 0 | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 16, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.88M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2.02M | Jun 16, 2025 |
| FY2023 | Dec 31, 2022 | 15.07M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 9.67M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 52.67M | Mar 31, 2022 |
| FY2015 | Dec 31, 2015 | 27.91M | Jun 10, 2016 |
| FY2015 | Dec 31, 2014 | 27.31M | Jun 10, 2016 |
| FY2014 | Dec 31, 2013 | 26.72M | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | 20.46M | Mar 31, 2014 |